{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:54Z","timestamp":1786119954456,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/ico.0b013e31820cd3f4","type":"journal-article","created":{"date-parts":[[2011,7,20]],"date-time":"2011-07-20T07:38:22Z","timestamp":1311147502000},"page":"1071-1077","source":"Crossref","is-referenced-by-count":13,"title":["Compensatory Growth Factor and Cytokine Response in Tears After Subconjunctival Bevacizumab Injection"],"prefix":"10.1097","volume":"30","author":[{"given":"Jae Hoon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeoun Suk","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210204","first-page":"89","article-title":"Inhibition of angiogenesis.","volume":"3","author":"Folkman","year":"1992","journal-title":"Semin Cancer Biol"},{"key":"R2-1-20210204","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00192885","article-title":"Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.","volume":"73","author":"Battegay","year":"1995","journal-title":"J Mol Med"},{"key":"R3-1-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy.","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"R4-1-20210204","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1442-9071.1996.tb01596.x","article-title":"Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor.","volume":"24","author":"Loughman","year":"1996","journal-title":"Aust N Z J Ophthalmol"},{"key":"R5-1-20210204","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.","volume":"146","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"key":"R6-1-20210204","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"R7-1-20210204","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00417-006-0466-4","article-title":"Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.","volume":"245","author":"Lazic","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-1-20210204","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"key":"R9-1-20210204","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R10-1-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R11-1-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome.","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"R12-1-20210204","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R13-1-20210204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R14-1-20210204","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archopht.125.10.1363","article-title":"Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.","volume":"125","author":"Sawada","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R15-1-20210204","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/IAE.0b013e31818358b2","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.","volume":"28","author":"Chan","year":"2008","journal-title":"Retina"},{"key":"R16-1-20210204","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","article-title":"Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.","volume":"115","author":"Zhu","year":"2008","journal-title":"Ophthalmology"},{"key":"R17-1-20210204","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archopht.1991.01080070117048","article-title":"Altered distribution of basic fibroblast growth factor in diabetic retinopathy.","volume":"109","author":"Hanneken","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R18-1-20210204","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bjo.78.9.714","article-title":"Retinal and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy.","volume":"78","author":"Patel","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R19-1-20210204","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI116877","article-title":"Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.","volume":"92","author":"Meyer-Schwickerath","year":"1993","journal-title":"J Clin Invest"},{"key":"R20-1-20210204","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bjo.2006.101485","article-title":"Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.","volume":"91","author":"Malvitte","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R21-1-20210204","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.a.20272","article-title":"Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients.","volume":"69","author":"Prunet","year":"2006","journal-title":"Cytometry A"},{"key":"R22-1-20210204","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1350-9462(99)00007-5","article-title":"Growth factors: importance in wound healing and maintenance of transparency of cornea.","volume":"19","author":"Imanishi","year":"2000","journal-title":"Prog Retin Eye Res"},{"key":"R23-1-20210204","first-page":"987","article-title":"Proinflammatory cytokines induce RANTES and MCP-1 synthesis in human corneal keratocytes but not in corneal epithelial cells. Beta-chemokine synthesis in corneal cells.","volume":"37","author":"Tran","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-1-20210204","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1350-9462(01)00008-8","article-title":"The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells.","volume":"20","author":"Wilson","year":"2001","journal-title":"Prog Retin Eye Res"},{"key":"R25-1-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R26-1-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R27-1-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R28-1-20210204","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00003226-198906000-00008","article-title":"Treatment of rabbit corneal alkali wounds with human epidermal growth factor.","volume":"8","author":"Chung","year":"1989","journal-title":"Cornea"},{"key":"R29-1-20210204","first-page":"401","article-title":"Recombinant human epidermal growth factor and corneal neovascularization.","volume":"36","author":"Nezu","year":"1992","journal-title":"Jpn J Ophthalmol"},{"key":"R30-1-20210204","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1350-9462(98)00017-2","article-title":"Stromal-epithelial interactions in the cornea.","volume":"18","author":"Wilson","year":"1999","journal-title":"Prog Retin Eye Res"},{"key":"R31-1-20210204","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0039-6257(96)80005-1","article-title":"Corneal endothelium and growth factors.","volume":"41","author":"Hoppenreijs","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"R32-1-20210204","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00055735-200408000-00006","article-title":"Corneal wound healing.","volume":"15","author":"Kuo","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R33-1-20210204","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization.","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201110000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:34:15Z","timestamp":1786044855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201110000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31820cd3f4","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}